Onco-Innovations Partners with Inka Health to Enhance Cancer Treatment

Onco-Innovations Limited has entered a letter of intent with Inka Health Corp. to leverage Inka's AI-driven SynoGraph™ technology. This strategic move aims to boost precision oncology and de-risk drug development processes. The agreement involves Onco acquiring all of Inka's outstanding shares, valued at $3 million, in exchange for Onco's common shares, subject to due diligence.

Inka Health, a Canadian software firm, uses advanced analytics to revolutionize clinical research. Their platform offers insights into disease mechanisms, potentially reducing the time and cost of drug discovery. Noteworthy collaborations, including with AstraZeneca Canada, demonstrate Inka's capability in precision medicine.

The healthcare AI market is growing rapidly, with North America leading the charge. Onco's CEO, Thomas O'Shaughnessy, expressed enthusiasm for the potential acquisition, highlighting its impact on cancer detection and treatment improvements.